(MENAFN- GlobeNewsWire - Nasdaq) Opportunities in the NSCLC market include the adoption of targeted and immunotherapies such as PD-1/PD-L1 inhibitors, the potential in Asia Pacific driven by rising prevalence, and advancements in personalized treatments through biomarker-driven therapy. Growth is also supported by increasing R&D and healthcare investment.

Dublin, Oct. 15, 2025 (GLOBE NEWSWIRE) -- The "Non-Small Cell Lung Cancer Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2025 To 2033" report has been added to ResearchAndMarkets's offering.
The global non-small cell lung cancer (NSCLC) market is projected to expand at a CAGR of 10.3% from 2025 to 2033, driven by the rising prevalence of lung cancer, increasing adoption of targeted and immunotherapy drugs, and growing investment in oncology research.

This study report represents an analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.
NSCLC accounts for approximately 85% of all lung cancer cases worldwide, making it a critical area of focus in oncology drug development. Advancements in biomarker-driven therapies and the availability of personalized treatment regimens are reshaping clinical practices and expanding treatment options.

The current report comprises quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends & technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Increasing Adoption of Targeted and Immunotherapies
Targeted therapies and immunotherapies are transforming the NSCLC treatment landscape. The use of immune checkpoint inhibitors, such as PD-1/PD-L1 inhibitors, and targeted drugs against EGFR, ALK, and ROS1 mutations have significantly improved patient survival rates. Expanding genetic testing for patients with NSCLC is enabling the adoption of precision medicine, while ongoing clinical trials continue to introduce novel drugs targeting rare mutations. The shift toward combination therapies involving chemotherapy and immunotherapy is also contributing to market growth.
High Cost of Therapies and Access Barriers
Despite the promising outlook, challenges such as the high cost of targeted and immunotherapy treatments and limited access in low- and middle-income regions hinder market penetration. Long treatment durations, adverse side effects, and variability in patient response remain significant barriers. Furthermore, the complexity of drug development and regulatory approval processes adds to the challenges faced by pharmaceutical companies. Nonetheless, increasing government healthcare spending, broader insurance coverage, and ongoing R&D collaborations are expected to ease these constraints.
Market Segmentation by Type
The market is segmented into adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and other types. In 2024, adenocarcinoma accounted for the largest share due to its high prevalence, particularly among non-smokers. Squamous cell carcinoma remains a significant segment, especially in smokers, while large cell carcinoma and other types are less common but require specialized treatment approaches.
Market Segmentation by Treatment
By treatment, the market is divided into chemotherapy, immunotherapy, targeted therapy, and other treatment types. In 2024, immunotherapy dominated the market, driven by approvals of immune checkpoint inhibitors and growing adoption in first-line therapy. Targeted therapy is expanding rapidly with the identification of new biomarkers and rising use of next-generation sequencing. Chemotherapy continues to play a role, particularly in combination regimens, while other treatments include palliative care and supportive interventions.
Regional Insights
In 2024, North America led the NSCLC market, with the U.S. at the forefront due to strong healthcare infrastructure, widespread adoption of biomarker testing, and high access to advanced therapies. Europe followed, supported by robust oncology pipelines and national cancer care strategies in countries like Germany, France, and the UK. Asia Pacific is the fastest-growing region, driven by rising lung cancer prevalence in China, Japan, and India, combined with improving access to innovative drugs. Latin America and Middle East & Africa represent emerging markets where government initiatives and partnerships with pharmaceutical companies are expanding access to oncology treatments.
Competitive Landscape
The 2024 market was dominated by global pharmaceutical leaders investing heavily in oncology R&D. F. Hoffmann-La Roche, AstraZeneca, Merck & Co., Bristol-Myers Squibb, and Novartis led the market with extensive portfolios in targeted therapy and immuno-oncology. Pfizer, Eli Lilly, and Janssen Biotech maintained significant presence in chemotherapy and targeted treatment options. Sanofi, Takeda, and AbbVie expanded their pipelines through collaborations and acquisitions. Astellas Pharma, Merus, Sun Pharmaceutical, and Xcovery contributed with specialized or regionally focused oncology solutions. Competitive differentiation is shaped by drug efficacy, safety, biomarker targeting, pipeline innovation, and global distribution reach.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Non-Small Cell Lung Cancer market?
• What are the key investment pockets concerning product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2033.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Non-Small Cell Lung Cancer market?
• Which is the largest regional market for Non-Small Cell Lung Cancer market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Non-Small Cell Lung Cancer market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Non-Small Cell Lung Cancer market worldwide?

Companies Featured

• Astellas Pharma
• AstraZeneca
• Eli Lilly
• F. Hoffmann La Roche
• Janssen Biotech
• Merck & Co.
• Novartis
• Pfizer
• Sanofi
• Sun Pharmaceutical

Market Segmentation

Type

• Adenocarcinoma
• Squamous cell carcinoma
• Large cell carcinoma
• Other types

Treatment

• Chemotherapy
• Immunotherapy
• Targeted therapy
• Other treatment types

Gender

• Male
• Female

End Use

• Hospitals
• Specialty clinics
• Other end use

Region Segment (2023 - 2033; US$ Million)

• North America
• U.S.
• Canada
• Rest of North America
• UK and European Union
• UK
• Germany
• Spain
• Italy
• France
• Rest of Europe
• Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific
• Latin America
• Brazil
• Mexico
• Rest of Latin America
• Middle East and Africa
• GCC
• Africa
• Rest of Middle East and Africa

For more information about this report visit

About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: CONTACT: Laura Wood,Senior Press Manager ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

MENAFN15102025004107003653ID1110199663